Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

And its investments in AI could, eventually, lead to important monetization opportunities even beyond advertising, perhaps ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

Recursion is hosting about 60 investors and analysts at its headquarters in Utah. It has generated tons of data with AI and robots, aiming to find a better way to make drugs. Recursion, which has four ...

Recursion Pharmaceuticals presents a compelling investment opportunity due to its AI-driven drug discovery platform, solid financials, and diverse pipeline, setting it apart from competitors like ...

Management expressed confidence in achieving further milestones in 2025, supported by partnerships with Roche and Sanofi. CEO Gibson noted that the partnership milestones generated $45 million in cash ...

The company published its latest quarterly earnings report this morning. It continues to draw limited revenue, while its costs are growing notably. For the quarter, Recursion -- which although a ...

Recursion announced the results from its Phase 2 SYCAMORE trial of REC-994, a treatment for Cerebral Cavernous Malformations (CCM), at the International Stroke Conference. The trial met its primary ...